Highest-materiality recent filing
Talphera reports Q4 net loss $3.8M; NEPHRO CRRT study 50% enrolled, all 12 sites active
Cash and investments $20.4M at Dec 31, 2025; net loss $3.8M ($0.06 per share) vs $1.9M ($0.07) in Q4 2024.
Talphera closes $4.1M third tranche of private placement, issuing shares and warrants
Third closing on March 13, 2026: 639,931 shares at $0.586/share and pre-funded warrants for 6,399,316 shares at $0.585 each.
Talphera receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Received Nasdaq notice on March 11, 2026 for non-compliance with minimum bid price of $1.00 per share.
Talphera Q3 net loss $4.4M; cash $21.3M; Niyad study on track for H1 2026
Net loss $4.4M ($0.11/sh) vs $3.4M ($0.13/sh) in Q3 2024.
Talphera raises ~$1.6M in final private placement tranches; regains Nasdaq compliance
Issued 1,023,890 shares at $0.586/share and pre-funded warrants for 1,706,484 shares at $0.585/warrant.
Talphera raises ~$17M in private placement with CorMedix; second closing tied to NEPHRO CRRT
Issued 25,036,360 shares at $0.55/share and pre-funded warrants for 5,845,455 shares; gross proceeds ~$17M.
Talphera Q2 net loss $3.5M ($0.10/sh); NEPHRO study enrollment accelerates
15 patients enrolled in NEPHRO registrational study; on track for completion by end of 2025, PMA submission Q1 2026.
Talphera gets 180-day extension to regain Nasdaq $1.00 bid price compliance through Dec 1, 2025
Received Nasdaq notice granting second 180-day compliance period until December 1, 2025 for minimum bid price requirement.
Talphera Q1 2025 net loss narrows to $0.10/share; NEPHRO study reduced to 70 patients
Net loss from continuing ops $2.7M vs $4.0M YoY; diluted EPS loss $0.10 vs $0.16.
Gross proceeds of ~$4.9M from first closing: 3,405,118 shares and pre-funded warrants for 4,999,316 shares at $0.586/share.
Talphera reports Q4 2024 net loss $1.9M; FDA cuts NEPHRO study size to 70 patients
FDA agreed to reduce NEPHRO CRRT study from 166 to 70 patients; study completion targeted by end of 2025.
Talphera receives Nasdaq notice for non-compliance with $1.00 minimum bid price
Received Nasdaq notice on Dec 6, 2024 for failure to maintain minimum bid price of $1.00 for 30 consecutive business days.
Talphera receives Nasdaq deficiency notice for stockholders' equity below $10M
Stockholders' equity as of Sept 30, 2024 was $9.641M, below Nasdaq's $10M minimum for Global Market.
Talphera Q3 net loss widens to $3.4M; NEPHRO CRRT study enrollment underway
Net loss $3.4M ($0.13/share) vs $1.4M ($0.08) in Q3 2023; cash and investments $11.1M.
Talphera reports Q1 2024 net loss $4.0M; NEPHRO study enrollment delayed, guidance revised
Net loss from continuing ops $4.0M vs income $0.1M in Q1 2023; basic EPS -$0.16.
Talphera Q4 net loss $4.5M; cash $9.4M; Niyad study enrollment imminent; $26M committed
Net loss from continuing ops of $4.5M ($0.25/sh) vs $5.9M ($1.00/sh) in Q4 2022; revenues $0.3M.
Talphera secures $26M total capital commitment: $6M upfront equity, $8M royalty monetization
$6M upfront equity from Nantahala Capital and Rosalind Advisors; $10M additional upon positive NEPHRO trial data, $2M if stock price >=$0.92 for 5 days.
Talphera sells DSUVIA/DZUVEO royalty rights to XOMA for $8M upfront
Sold rights to royalty and milestone payments from Vertical Pharma to XOMA for $8M cash.
AcelRx Q3 net loss $1.4M; Niyad gets FDA IDE approval, registrational study to start Q4
Net loss from continuing ops $1.4M ($0.08/sh); revenue $0.1M from DSUVIA royalty.
AcelRx receives Nasdaq non-compliance notice for bid price below $1.00
Received Nasdaq notice on Oct 18, 2023 for failure to maintain minimum bid price of $1.00 for 30 consecutive business days.
FDA declines to issue EUA for AcelRx's Niyad; company will pursue PMA by 2024
FDA notified AcelRx on Sept 22, 2023 it declined EUA for Niyad (nafamostat) in CRRT due to prioritization of other requests.
AcelRx Q2 net loss $4.4M; raises $10M in private placement; Niyad EUA pending
Net loss attributable to common shareholders $4.4M ($0.40/share) vs net income $63.2M in Q2 2022.
AcelRx raises ~$10M via private placement of common stock and warrants
Gross proceeds ~$10M from sale of 5.34M shares, pre-funded warrants for 2.01M shares, and Series A/B warrants for 7.35M shares each at $1.11 exercise price; combined price $1.36.
AcelRx cures Nasdaq minimum bid price deficiency; compliance regained
Nasdaq had notified AcelRx on April 26, 2023 of non-compliance with the $1.00 minimum bid price rule.
AcelRx Q1 net loss $8.2M; DSUVIA divestiture closed, Niyad EUA submitted
Net loss $8.2M ($0.75/share) vs $8.7M loss in Q1 2022; cash $13.4M at March 31, 2023.
AcelRx receives Nasdaq deficiency notice for bid price below $1.00 per share
Notice dated April 26, 2023; requires minimum $1.00 bid price for continued listing on Nasdaq Global Market.
AcelRx closes sale of DSUVIA to Alora for up to $116.5M in milestones; repays Oxford loan
Closed divestment of DSUVIA to Alora Pharmaceuticals on April 3, 2023; received ~$2.7M from Aguettant and Alora at closing.
Non-reliance on Q2 and Q3 2022 financials due to EPS calculation error (two-class method for warrants); no impact on cash, revenue, or net income.
AcelRx sells DSUVIA/DZUVEO assets to Vertical Pharma for up to $116.5M milestones plus royalties
AcelRx to sell DSUVIA/DZUVEO sufentanil tablet to Vertical Pharma; gets up to $116.5M in sales milestones and 15% net sales royalty.
AcelRx raises ~$7.5M via registered direct offering of common stock and warrants
Sold 748,744 shares, pre-funded warrants for 2,632,898 shares, and common warrants for 4,227,052 shares at $2.22625 combined price.
Patheon terminates manufacturing agreement with AcelRx; effective May 31, 2024
Patheon provided notice on Nov 29, 2022 to terminate the MSA, originally dated Dec 12, 2012.
AcelRx reports Q3 net loss of $6.9M, DSUVIA sales up 217% YoY to $0.5M
DSUVIA net sales $0.5M in Q3 2022, up 217% vs Q3 2021; units sold 1,032 vs 371.
AcelRx effects 1:20 reverse stock split; redeems Series A Preferred for $315K
1:20 reverse stock split effective Oct 25, 2022; trading on split-adjusted basis on Nasdaq from Oct 26.
AcelRx Q2 net income $70.7M on $84.1M debt gain; revenue $0.6M
Net income of $70.7M ($0.48 diluted EPS) vs net loss of $9.9M in Q2 2021, driven by $84.1M gain on extinguishment of royalty monetization liability.
AcelRx enters $300K private placement with Lincoln Park; sets reverse split vote for Sep 23
Issued 3,000 Series A Preferred shares and warrant to buy 1.6M common shares at $0.2033; aggregate $300K.
Upon Dr. Palmer’s retirement, Dr. Shakil Aslam, currently the Company’s Chief Development Officer, will assume the position of the Company’s Chief Medical Officer.
On August 12, 2024, Pamela P. Palmer, MD, PhD, the Company’s Chief Medical Officer and co-founder, notified the Company that she plans to retire and resign from the Company effective October 1, 2024.
On February 26, 2024, Richard Afable, M.D. and Howard B. Rosen resigned as members of the board of directors of Talphera, Inc. (the "Company"), and any and all committees thereof, effective immediately.
On February 26, 2024, Richard Afable, M.D. and Howard B. Rosen resigned as members of the board of directors of Talphera, Inc. (the "Company"), and any and all committees thereof, effective immediately.
On February 28, 2024, Pamela P. Palmer, M.D., Ph.D. resigned as a member of the Company's board of directors effective immediately.
the board of directors of the Company appointed Abhinav Jain to serve as a Class II Director
On February 23, 2022, Mark G. Edwards advised the board of directors of AcelRx Pharmaceuticals, Inc. of his intention to resign as a member of the board of directors effective March 31, 2022.
On November 20, 2021, the Board of Directors (the “Board”) of AcelRx Pharmaceuticals, Inc. (the “Company”) appointed Jill M. Broadfoot a Class I director of the Board, effective November 20, 2021, to serve until the expiration of her term at the 2024 annual meeting of stockholders.
Max materiality 0.85 · Median 0.65 · Most common event other_material